Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16+
SponsorImperial College London
About this trial
Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years.
Findings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.
Eligibility criteria
Qualifiers
Have a high risk primary colorectal malignancy
Have a negative CT or includes no confirmatory evidence of liver metastases
Is able to undergo treatment if liver metastasis is found
Have provided written informed consent to participate in the study
Disqualifiers
Have had a previous colorectal malignancy
Have metastatic disease
Have a synchronous second malignancy
Are contraindicated for MRI
Trial design
Treatments tested in this trial
- Diffusion Weighted MRI scan
Treatment groups
282 Participants
are divided into 1 treatment groupSponsors and collaborators
Imperial College London
Lead sponsor
Pelican Cancer Foundation
Collaborator
Source ClinicalTrials.gov